Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert H Collins

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Blood Advances|February 3, 2026
Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML ReportJoshua F Zeidner, Jayanshu Jain, Rina Li Welkie, et al.
Blood|January 27, 2017
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemiaViktoras Frismantas, Maria Pamela Dobay, Anna Rinaldi, et al.
Blood Advances|October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AMLSheng F Cai, Ying Huang, Jennie R Lance, et al.
Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances|October 31, 2022
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlatesAntoine N Saliba, Scott H Kaufmann, Eytan M Stein, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
The New England Journal of Medicine|June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
Nature|October 19, 2018
Functional genomic landscape of acute myeloid leukaemiaJeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, et al.
Cancer Cell|July 22, 2022
Integrative analysis of drug response and clinical outcome in acute myeloid leukemiaDaniel Bottomly, Nicola Long, Anna Reister Schultz, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Blood Advances|February 3, 2026
Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML ReportJoshua F Zeidner, Jayanshu Jain, Rina Li Welkie, et al.
Blood|January 27, 2017
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemiaViktoras Frismantas, Maria Pamela Dobay, Anna Rinaldi, et al.
Blood Advances|October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AMLSheng F Cai, Ying Huang, Jennie R Lance, et al.
Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances|October 31, 2022
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlatesAntoine N Saliba, Scott H Kaufmann, Eytan M Stein, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
The New England Journal of Medicine|June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
Nature|October 19, 2018
Functional genomic landscape of acute myeloid leukaemiaJeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, et al.
Cancer Cell|July 22, 2022
Integrative analysis of drug response and clinical outcome in acute myeloid leukemiaDaniel Bottomly, Nicola Long, Anna Reister Schultz, et al.
Pageof 5